135 related articles for article (PubMed ID: 27910191)
41. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp.
Shalit I; Shadkchan Y; Mircus G; Osherov N
Med Mycol; 2009; 47(5):457-62. PubMed ID: 18720217
[TBL] [Abstract][Full Text] [Related]
42. Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.
Soler L; Rodriguez JC; Belda S; Cremades R; Ruiz-Garcia M; Lopez P; Royo G
J Chemother; 2010 Aug; 22(4):283-4. PubMed ID: 20685636
[No Abstract] [Full Text] [Related]
43. In vitro activity of voriconazole against selected fungi.
McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
[TBL] [Abstract][Full Text] [Related]
44. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
45. Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.
Abastabar M; Al-Hatmi AMS; Vafaei Moghaddam M; de Hoog GS; Haghani I; Aghili SR; Shokohi T; Hedayati MT; Daie Ghazvini R; Kachuei R; Rezaei-Matehkolaei A; Makimura K; Meis JF; Badali H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530844
[TBL] [Abstract][Full Text] [Related]
46. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Chen TC; Chen YH; Chen YC; Lu PL
Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
[TBL] [Abstract][Full Text] [Related]
47. Treatment of Alternaria keratitis with intrastromal and topical caspofungin in combination with intrastromal, topical, and oral voriconazole.
Neoh CF; Leung L; Vajpayee RB; Stewart K; Kong DC
Ann Pharmacother; 2011 May; 45(5):e24. PubMed ID: 21521864
[TBL] [Abstract][Full Text] [Related]
48. In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals.
Ahmed SA; de Hoog GS; Stevens DA; Fahal AH; van de Sande WW
Med Mycol; 2015 Apr; 53(3):295-301. PubMed ID: 25631481
[TBL] [Abstract][Full Text] [Related]
49. In vitro susceptibility of Pythium insidiosum and a Lagenidium sp to itraconazole, posaconazole, voriconazole, terbinafine, caspofungin, and mefenoxam.
Brown TA; Grooters AM; Hosgood GL
Am J Vet Res; 2008 Nov; 69(11):1463-8. PubMed ID: 18980428
[TBL] [Abstract][Full Text] [Related]
50. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
[TBL] [Abstract][Full Text] [Related]
51. Rhinocladiella aquaspersa, proven agent of verrucous skin infection and a novel type of chromoblastomycosis.
Badali H; Bonifaz A; Barrón-Tapia T; Vázquez-González D; Estrada-Aguilar L; Oliveira NM; Sobral Filho JF; Guarro J; Meis JF; De Hoog GS
Med Mycol; 2010 Aug; 48(5):696-703. PubMed ID: 20055741
[TBL] [Abstract][Full Text] [Related]
52. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Mariné M; Bom VL; de Castro PA; Winkelstroter LK; Ramalho LN; Brown NA; Goldman GH
Virulence; 2015; 6(5):476-86. PubMed ID: 25751127
[TBL] [Abstract][Full Text] [Related]
53. Exogenous fungal endophthalmitis: an analysis of isolates and susceptibilities to antifungal agents over a 20-year period (1990-2010).
Silva RA; Sridhar J; Miller D; Wykoff CC; Flynn HW
Am J Ophthalmol; 2015 Feb; 159(2):257-64.e1. PubMed ID: 25449001
[TBL] [Abstract][Full Text] [Related]
54. Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium.
Spader TB; Venturini TP; Rossato L; Denardi LB; Cavalheiro PB; Botton SA; Santurio JM; Alves SH
Rev Iberoam Micol; 2013; 30(3):200-4. PubMed ID: 23402831
[TBL] [Abstract][Full Text] [Related]
55.
Roels D; Coorevits L; Lagrou K
Am J Ophthalmol Case Rep; 2020 Sep; 19():100791. PubMed ID: 32637731
[TBL] [Abstract][Full Text] [Related]
56. Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study.
Tortorano AM; Dannaoui E; Meletiadis J; Mallie M; Viviani MA; Piens MA; Rigoni AL; Bastide JM; Grillot R;
J Chemother; 2002 Jun; 14(3):246-52. PubMed ID: 12120878
[TBL] [Abstract][Full Text] [Related]
57. Roussoella solani causing keratomycosis, with an observed both sexual and asexual morphs.
Mochizuki K; Nishida T; Murata K; Ishida K; Sunada A; Asari S; Ohkusu K; Tanaka K
J Infect Chemother; 2017 Sep; 23(9):651-654. PubMed ID: 28389166
[TBL] [Abstract][Full Text] [Related]
58. The effects of caspofungin and voriconazole in experimental Candida endophthalmitis.
Kusbeci T; Avci B; Cetinkaya Z; Ozturk F; Yavas G; Ermis SS; Inan UU
Curr Eye Res; 2007 Jan; 32(1):57-64. PubMed ID: 17364736
[TBL] [Abstract][Full Text] [Related]
59. Filamentous fungal infections of the cornea: a global overview of epidemiology and drug sensitivity.
Kredics L; Narendran V; Shobana CS; Vágvölgyi C; Manikandan P;
Mycoses; 2015 Apr; 58(4):243-60. PubMed ID: 25728367
[TBL] [Abstract][Full Text] [Related]
60. Successful topical application of caspofungin in the treatment of fungal keratitis refractory to voriconazole.
Hurtado-Sarrió M; Duch-Samper A; Cisneros-Lanuza A; Díaz-Llopis M; Peman-Garcíia J; Vazquez-Polo A
Arch Ophthalmol; 2010 Jul; 128(7):941-2. PubMed ID: 20625061
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
